日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

P-1863. Maternal Mycobacterial-Specific T-cell Signatures and Infant Risk of Mycobacterium tuberculosis Infection

P-1863. 母体结核分枝杆菌特异性T细胞特征与婴儿结核分枝杆菌感染风险

Su, Andrew; Lee, HoJoon; Tran, Minh; Dela Cruz, Richard C; Sathe, Anuja; Bai, Xiangqi; Wichmann, Ignacio; Pflieger, Lance; Moulton, Bryce; Barker, Tyler; Haslem, Derrick; Jones, David; Nadauld, Lincoln; Nguyen, Quan; Ji, Hanlee P; Rhodes, Terence; Himmelfarb, Talia; Warr, Alex; Kinuthia, John; Matemo, Daniel; Mecha, Jerphason O; LaCourse, Sylvia M; John-Stewart, Grace; Harrington, Whitney; Hawn, Thomas

Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).

托珠单抗治疗 COVID-19 肺炎住院患者:一项随机对照试验的疗效、安全性、病毒清除率和抗体反应 (COVACTA)

Rosas Ivan O, Bräu Norbert, Waters Michael, Go Ronaldo C, Malhotra Atul, Hunter Bradley D, Bhagani Sanjay, Skiest Daniel, Savic Sinisa, Douglas Ivor S, Garcia-Diaz Julia, Aziz Mariam S, Cooper Nichola, Youngstein Taryn, Sorbo Lorenzo Del, Zerda David J De La, Ustianowski Andrew, Gracian Antonio Cubillo, Blyth Kevin G, Carratalà Jordi, François Bruno, Benfield Thomas, Haslem Derrick, Bonfanti Paolo, van der Leest Cor H, Rohatgi Nidhi, Wiese Lothar, Luyt Charles Edouard, Bauer Rebecca N, Cai Fang, Lee Ivan T, Matharu Balpreet, Metcalf Louis, Wildum Steffen, Graham Emily, Tsai Larry, Bao Min

Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.

在随机对照试验中,使用托珠单抗治疗的2019冠状病毒病患者的预后和预测生物标志物

Tom Jennifer, Bao Min, Tsai Larry, Qamra Aditi, Summers David, Carrasco-Triguero Montserrat, McBride Jacqueline, Rosenberger Carrie M, Lin Celia J F, Stubbings William, Blyth Kevin G, Carratalà Jordi, François Bruno, Benfield Thomas, Haslem Derrick, Bonfanti Paolo, van der Leest Cor H, Rohatgi Nidhi, Wiese Lothar, Luyt Charles Edouard, Kheradmand Farrah, Rosas Ivan O, Cai Fang

The Development of an Infrastructure to Facilitate the Use of Whole Genome Sequencing for Population Health

构建基础设施以促进全基因组测序在人群健康中的应用

Walton, Nephi A; Hafen, Brent; Graceffo, Sara; Sutherland, Nykole; Emmerson, Melanie; Palmquist, Rachel; Formea, Christine M; Purcell, Maricel; Heale, Bret; Brown, Matthew A; Danford, Christopher J; Rachamadugu, Sumathi I; Person, Thomas N; Shortt, Katherine A; Christensen, G Bryce; Evans, Jared M; Raghunath, Sharanya; Johnson, Christopher P; Knight, Stacey; Le, Viet T; Anderson, Jeffrey L; Van Meter, Margaret; Reading, Teresa; Haslem, Derrick S; Hansen, Ivy C; Batcher, Betsey; Barker, Tyler; Sheffield, Travis J; Yandava, Bhaskara; Taylor, David P; Ranade-Kharkar, Pallavi; Giauque, Christopher C; Eyring, Kenneth R; Breinholt, Jesse W; Miller, Mickey R; Carter, Payton R; Gillman, Jason L; Gunn, Andrew W; Knowlton, Kirk U; Bonkowsky, Joshua L; Stefansson, Kari; Nadauld, Lincoln D; McLeod, Howard L

Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs

精准肿瘤学在晚期癌症患者中可提高总体生存率,并降低每周医疗保健成本。

Haslem, Derrick S; Chakravarty, Ingo; Fulde, Gail; Gilbert, Heather; Tudor, Brian P; Lin, Karen; Ford, James M; Nadauld, Lincoln D

Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine

曲妥珠单抗耐药的人表皮生长因子受体2阳性结肠癌的精准肿瘤治疗策略:Ado-曲妥珠单抗恩坦辛治疗获得持久疗效的病例报告

Haslem, Derrick S; Ji, Hanlee P; Ford, James M; Nadauld, Lincoln D

A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs

一项针对晚期癌症患者精准医疗疗效的回顾性分析显示,在不增加医疗保健成本的情况下,患者的无进展生存期得到改善。

Haslem, Derrick S; Van Norman, S Burke; Fulde, Gail; Knighton, Andrew J; Belnap, Tom; Butler, Allison M; Rhagunath, Sharanya; Newman, David; Gilbert, Heather; Tudor, Brian P; Lin, Karen; Stone, Gary R; Loughmiller, David L; Mishra, Pravin J; Srivastava, Rajendu; Ford, James M; Nadauld, Lincoln D